Sintilimab improves survival in advanced non-metastatic nasopharyngeal carcinoma
1. Patients in the sintilimab group reported a significantly greater event-free survival at 36 months compared to the standard therapy ...
Tag: nasopharyngeal carcinoma
Hyperfractionated radiotherapy reduces complication rates compared to standard fractionation for locally advanced nasopharyngeal carcinoma
1. Fewer patients in the hyperfractionation group reported grade 3 or worse late radiation-induced complications compared to the standard fractionation ...
#StudyGraphics: Concomitant chemoradiotherapy improves survival in elderly adults with locally advanced head and neck squamous cell carcinoma
Click to read this study in JAMA Network Open.
#VisualAbstract: Adjuvant capecitabine improves clinical outcomes in patients with locally advanced nasopharyngeal carcinoma
Click to read this study in JAMA Oncology.
#VisualAbstract: Induction chemotherapy with cisplatin plus gemcitabine in addition to concurrent chemotherapy improves survival for nasopharyngeal carcinoma
Click to read this study in the Journal of Clinical Oncology.
Radiotherapy alone noninferior to concurrent chemoradiotherapy survival without disease relapse in patients with low-risk nasopharyngeal carcinoma
1. Patients with low-risk nasopharyngeal carcinoma did not have significantly different disease-free survival rates whether they received radiotherapy alone or ...
#VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma
Click to read this study in the Journal of Clinical Oncology.
#VisualAbstract: Upper neck irradiation is noninferior to whole neck irradiation for newly diagnosed nasopharyngeal carcinoma
Click to read this study in The Lancet Oncology.
Induction chemotherapy with paclitaxel, cisplatin and capecitabine showed promising clinical and safety response to treat advanced nasopharyngeal carcinoma
1. The failure-free-survival at 3 years for induction chemotherapy with paclitaxel, cisplatin and capecitabine group was 83.5% versus 68.9% in ...